drugset / Trial / NCT06903702
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
Phase 2
Not yet recruiting
100 enrolled
Memorial Sloan Kettering Cancer Center
Genentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out if an allogeneic hematopoietic stem cell transplant (HSCT) or maintenance therapy with azacitidine and venetoclax is more effective at keeping AML from coming back (relapsing).
Timeline
- Start
- 2026-08-04
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | — |
| Subject | Venetoclax | Small molecule | — | Oral |